Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
RTNominal down29.050 -0.300 (-1.022%)

29/10/2021 15:40

Junshi Bio (01877) gets acceptance notice from NMPA

[ET Net News Agency, 29 October 2021] Shanghai Junshi Biosciences Co., Ltd. (01877)
said the company has received the Acceptance Notice issued by the National Medical
Products Administration. The investigational new drug application for the JS026 injection
has been accepted.
JS026 injection is a recombinant fully human monoclonal antibody, which is mainly used
to prevent and treat the COVID-19. JS026 targets the S1 subunit of the SARS-CoV-2 spike
protein, binding to the receptor binding domain (RBD) with high affinity, blocking the
binding between RBD and the angiotensin converting enzyme 2 (ACE2) in the host cell
surface receptor, thereby further blocking the infection of host cells by SARS-CoV-2. (RC)

Remark: Real time quote last updated: 22/03/2023 14:38
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2023 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.